Treatment with biosimilar insulin in routine clinical practice in Slovakia: case reports
Authors:
Rid Bugáňová 1; Jana Ročiaková 2; Jozef Lacka 3; Zbynek Schroner 4,5
Authors‘ workplace:
MEDIVASA s. r. o., Žilina
1; Interná a diabetologická ambulancia, Žilina
2; JAL s. r. o., Trnava
3; Lekárska fakulta UPJŠ v Košiciach
4; SchronerMED s. r. o., Košice
5
Published in:
Diab Obez 2022; 22(43): 34-38
Category:
Case studies
Sources
1. Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Interná Med 2018; 18(1):31–47.
2. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced Hypoglycemia Risk with Insulin Glargine. Diabetes Care 2005; 28(4): 950–955. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.28.4.950>.
3. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of MedicalCare in Diabetesd 2018. Diabetes Care 2018; 41(Suppl 1): S73-S85. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18-S008>.
4. Matejička P. Polyneuropatie u pacientov s diabetes mellitus. Forum Diab 2018; 7(3): 140–146
5. Mazanec R, Martin Bojar M, Nedělka T. Diabetická neuropatia z pohledu neurologa. Neurol Praxi 2009; 10(6): 378–383.
6. Vondrová H. Diagnostika a diferenciálna diagnostika diabetické polyneuropatie. Neurol Praxi 2010; 11(1): 41–44.
7. Martinka E, Uličiansky V, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Interná Med 2018; 18(1): 31–47.
8. Rosenstock J, Dailey G, Massi-Benedetti M et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28(4): 950 - 955. Dostupné z DOI: <http://dx.doi.org/10.2337/diacare.28.4.950>.
9. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of MedicalCare in Diabetesd Diabetes Care 2018; 41(Suppl 1): S73-S85. Dostupné z DOI: <https://doi.org/10.2337/dc18-S008>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2022 Issue 43
-
All articles in this issue
- Editoriál
- Relationship of glycemic variability and diabetes risk factors in pregnant women
- From the adult type through NIDDM and second type of diabetes – what is coming thereafter?
- Cardiovascular effect of GLP-1 receptor agonists: meta-analyses suggest a class effect
- Use of SGLT2 inhibitors in type 2 diabetics at different stages of the cardiovascular continuum
- Cardiorenal benefits of GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus
- Treatment with biosimilar insulin in routine clinical practice in Slovakia: case reports
- Co-formulation of insulin degludec and insulin aspartate in realworld clinical practice: the ARISE study
- Adipocytokines as possible etiopathogenetic mechanisms leading to a higher incidence of autoimmune thyroiditis in patients with type 2 diabetes mellitus – enlarged study
- Effect of GLP-1 receptor agonists on postprandial lipaemia: commentary on a review article
- Spomienka na MUDr. Danielu Kuzmovú
- Virtuálny 26. World Diabetes Congress 2021
- 7. slovenský deň obezity: v liečbe obezity každý zaváži!
- Zbynek Schroner, Môžem sa opýtať, pán doktor? Najčastejšie otázky v ambulancii diabetológa
- Diabetes and obesity
- Journal archive
- Current issue
- About the journal
Most read in this issue
- Treatment with biosimilar insulin in routine clinical practice in Slovakia: case reports
- Relationship of glycemic variability and diabetes risk factors in pregnant women
- Cardiovascular effect of GLP-1 receptor agonists: meta-analyses suggest a class effect
- Use of SGLT2 inhibitors in type 2 diabetics at different stages of the cardiovascular continuum